Clinical Research Studies

RSV is a viral infection that can cause severe respiratory disease in infants and adults, especially in patients with certain health conditions that put them at increased risk of severe RSV and/or dangerous health complications. An investigational vaccine for RSV has been successfully tested in healthy populations but, the vaccine's safety and immunogenicity have not been tested among adults who a) have chronic health conditions that places them at higher risk of RSV disease, or b) who are immunocompromised. This study will help provide information about these important patient populations.

We are enrolling two substudy groups based on participant medical history (see the inclusion and exclusion criteria for each substudy below).

Substudy A:
• If you are eligible and agree to participate in Substudy A, you will be randomized to receive either the experimental RSV vaccine or a placebo vaccine (saline).
• You will be asked to complete 3 visits over 6 months (2 in-person visits, 1 televisit).
• You will be compensated $120 per in-person visit and $60 per televisit.

Substudy B:
• If you are eligible and agree to participate in Substudy B, you will receive 2 doses of the experimental RSV vaccine, approximately 1 month apart.
• You will be asked to complete 4 visits over 7 months (3 in-person visits, 1 televisit).
• You will be compensated $120 per in-person visit and $60 per televisit.